Ozempic. Wegovy. Mounjaro. If you have not heard these names from your employees yet, you will. GLP-1 receptor agonists, a class of medications originally developed for Type 2 diabetes, have become among the most discussed treatments in weight management. And they are landing directly on HR desks in the form of benefits questions, pharmacy cost inquiries, and requests for employer coverage.
As an HR leader, you do not need to become a pharmacist. But you do need to understand the basics, and you need to know what responsible, clinically supervised access to these medications looks like.
What GLP-1 Medications Actually Do
GLP-1 medications work by mimicking a hormone that regulates appetite, blood sugar, and gastric emptying. In clinical terms, they help patients feel fuller longer, reduce cravings, and lower blood sugar, which together produce meaningful, sustained weight loss for eligible patients.
The clinical results have been significant. In trials published in the New England Journal of Medicine, patients using semaglutide (the active ingredient in Wegovy) lost an average of 15% of their body weight over 68 weeks, results that far exceed most commercial weight loss programs.
The Risk of Unsupervised Access
Here is what concerns clinical professionals, and should concern HR leaders: a significant number of employees are accessing GLP-1 medications through online-only telehealth services that prescribe after a brief questionnaire, ship the medication, and provide no ongoing clinical oversight.
This is not physician-supervised care. It is a prescription delivery service. And without clinical monitoring, the risks are real:
- Side effects, including nausea, vomiting, and gastrointestinal complications, go unmanaged
- Dosing is not adjusted based on how the patient is responding
- Underlying conditions that affect eligibility are not evaluated
- Patients with contraindications, including certain thyroid conditions, may receive medications that are not safe for them
- When patients stop the medication without a maintenance plan, rapid weight regain is common
The critical distinction: A GLP-1 prescription is not a weight loss program. It is one tool within a program. Without physician oversight, nutritional structure, and a maintenance plan, medication alone produces temporary results and carries unnecessary risk.
What Responsible GLP-1 Access Looks Like
At Medi-Weightloss Berwyn and West Chester, GLP-1 medications are prescribed only after a comprehensive medical evaluation confirms eligibility. Patients are monitored weekly throughout their program, with dosing adjustments made based on clinical response. And every patient on a GLP-1 medication has a full treatment plan, not just a prescription.
For HR leaders, the message is straightforward: if your employees are going to use these medications, and many of them will, the safest and most effective way to do so is within a physician-supervised program, not through an online pharmacy with no clinical follow-up.
What This Means for Your Benefits Strategy
Some employers are beginning to add GLP-1 coverage to their pharmacy benefits, a decision that carries meaningful cost implications without a clinical framework to support it. Others are partnering with physician-supervised programs to ensure that medication is used appropriately, monitored carefully, and paired with the behavioral and nutritional support that makes it effective.
Medi-Weightloss Berwyn and West Chester is available to consult with HR and benefits teams on how to structure responsible GLP-1 access as part of a broader employee wellness strategy.
